Definium Therapeutics (NASDAQ:DFTX) Stock Price Target Raised at JPMorgan Chase & Co.

by · The Cerbat Gem

Definium Therapeutics (NASDAQ:DFTX – Get Free Report) had its price target boosted by stock analysts at JPMorgan Chase & Co. from $84.00 to $85.00 in a research note issued on Tuesday, Benzinga reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price target indicates a potential upside of 188.04% from the stock’s current price.

A number of other equities analysts have also weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Definium Therapeutics in a research report on Thursday, October 15th. Royal Bank Of Canada raised their price target on shares of Definium Therapeutics from $66.00 to $70.00 and gave the company an “outperform” rating in a report on Tuesday, November 10th. Canaccord Genuity Group set a $78.00 price target on shares of Definium Therapeutics and gave the company a “buy” rating in a report on Tuesday, September 15th. UBS Group reiterated a “buy” rating and issued a $70.00 price target on shares of Definium Therapeutics in a research note on Tuesday, September 15th. Finally, Wall Street Zen raised shares of Definium Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $66.29.

Read Our Latest Analysis on DFTX

Definium Therapeutics Stock Down 2.2%

Shares of DFTX stock traded down $0.65 during mid-day trading on Tuesday, hitting $29.51. The company’s stock had a trading volume of 1,054,033 shares, compared to its average volume of 2,195,387. The stock has a market cap of $3.97 billion, a price-to-earnings ratio of -9.49 and a beta of 2.23. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.95 and a current ratio of 15.53. Definium Therapeutics has a 52-week low of $10.46 and a 52-week high of $49.70. The business has a 50-day moving average price of $35.91 and a 200 day moving average price of $30.45.

Definium Therapeutics (NASDAQ:DFTX – Get Free Report) last released its quarterly earnings data on Monday, November 9th. The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.09. Research analysts predict that Definium Therapeutics will post -2.94 EPS for the current fiscal year.

Insider Transactions at Definium Therapeutics

In other Definium Therapeutics news, insider Mark Sullivan sold 14,051 shares of the business’s stock in a transaction dated Friday, September 25th. The stock was sold at an average price of $36.57, for a total transaction of $513,845.07. Following the completion of the sale, the insider directly owned 494,228 shares in the company, valued at $18,073,917.96. The trade was a 2.76% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Robert Barrow sold 31,550 shares of the business’s stock in a transaction dated Friday, September 25th. The shares were sold at an average price of $36.57, for a total value of $1,153,783.50. Following the sale, the chief executive officer owned 2,213,090 shares of the company’s stock, valued at approximately $80,932,701.30. This represents a 1.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 71,098 shares of company stock worth $2,626,115 in the last three months. 2.40% of the stock is owned by insiders.

Institutional Trading of Definium Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DFTX. Pinnacle Wealth Planning Services Inc. boosted its stake in shares of Definium Therapeutics by 2,928.0% during the 3rd quarter. Pinnacle Wealth Planning Services Inc. now owns 757 shares of the company’s stock worth $29,000 after acquiring an additional 732 shares during the last quarter. Nykredit A S bought a new position in Definium Therapeutics in the 2nd quarter worth $45,000. Bessemer Group Inc. purchased a new position in Definium Therapeutics during the third quarter valued at $42,000. GAMMA Investing LLC lifted its position in Definium Therapeutics by 28.3% during the third quarter. GAMMA Investing LLC now owns 1,555 shares of the company’s stock valued at $59,000 after purchasing an additional 343 shares in the last quarter. Finally, Allworth Financial LP bought a new stake in Definium Therapeutics during the second quarter valued at about $110,000. 27.91% of the stock is owned by hedge funds and other institutional investors.

About Definium Therapeutics

(Get Free Report)

Definium Therapeutics, Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026.

Further Reading